ES2184876T3 - Derivados de imidazol sustituidos en 1h-4(5). - Google Patents
Derivados de imidazol sustituidos en 1h-4(5).Info
- Publication number
- ES2184876T3 ES2184876T3 ES96921378T ES96921378T ES2184876T3 ES 2184876 T3 ES2184876 T3 ES 2184876T3 ES 96921378 T ES96921378 T ES 96921378T ES 96921378 T ES96921378 T ES 96921378T ES 2184876 T3 ES2184876 T3 ES 2184876T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- present
- lower alkyl
- disorders
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 229940123322 Histamine receptor agonist Drugs 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000009858 acid secretion Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003453 histamine agonist Substances 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 150000002460 imidazoles Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004899 motility Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Luminescent Compositions (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION ESTA DIRIGIDA A DERIVADOS DE IMIDAZOL 1H (B); O (C) EN LAS CUALES R SUB,1} ES ALQUILO INFERIOR O ALCOXI INFERIOR; R SUB,2}, R SUB,3}, R SUB,4}, R SUB,5}, R SUB,7} Y R SUB,8} SON CADA UNO INDEPENDIENTEMENTE HIDROGENO O ALQUILO INFERIOR; R SUB,6} ES HIDROGENO, ALQUILO INFERIOR O ALCOXI INFERIOR, Y R SUB,5} Y R SUB,6} PUEDEN TOMARSE CONJUNTAMENTE PARA FORMAR UN ANILLO DE 4, 5 O 6 ESLABONES. LOS COMPUESTOS DE FORMULA (I) PRESENTAN ACTIVIDAD AGONISTA DEL RECEPTOR DE HISTAMINA H SUB,3}. TAMBIEN SE CONTEMPLA QUE LAS SALES FARMACEUTICAMENTE ACEPTABLES Y LOS ESTEREOISOMEROS INDIVIDUALES DE LOS COMPUESTOS DE FORMULA (I) ANTERIOR, ASI COMO LAS MEZCLAS DE LOS MISMOS, SE ENCUENTRAN DENTRO DEL ALCANCE DE LA PRESENTE INVENCION. LA PRESENTE INVENCION TAMBIEN DESCRIBE COMPOSICIONES FARMACEUTICAS QUE INCLUYEN UN VEHICULO FARMACEUTICAMENTE ACEPTABLE JUNTO CON UNA CANTIDAD EFICAZ DE UN COMPUESTO DE FORMULA (I). LA PRESENTE INVENCION TAMBIEN DESCRIBE UN PROCEDIMIENTO PARA TRATAR TRASTORNOSEN LOS CUALES LA ACTIVACION DE LOS RECEPTORES H SUB,3} DE HISTAMINA PUEDE PRESENTAR IMPORTANCIA TERAPEUTICA, TALES COMO ALERGIA, INFLAMACION, ENFERMEDAD CARDIO (ES DECIR, HIPER ASCULAR, MIGRAÑA), TRASTORNOS GASTROINTESTINALES (SECRECION DE ACIDOS, MOTILIDAD) Y TRASTORNOS DE SNC QUE IMPLICAN TRASTORNOS PSIQUIATRICOS (ES DECIR, QUE INCLUYEN ANSIEDAD, TRASTORNOS MANIACO/DEPRESIVO, ESQUIZOFRENIA, TRASTORNOS OBSESIVO OS, ETC.).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47992595A | 1995-06-07 | 1995-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2184876T3 true ES2184876T3 (es) | 2003-04-16 |
Family
ID=23905996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96921378T Expired - Lifetime ES2184876T3 (es) | 1995-06-07 | 1996-06-06 | Derivados de imidazol sustituidos en 1h-4(5). |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0841923B1 (es) |
| JP (1) | JPH11507631A (es) |
| AT (1) | ATE224193T1 (es) |
| AU (1) | AU713166B2 (es) |
| CA (1) | CA2222652A1 (es) |
| DE (1) | DE69623784T2 (es) |
| DK (1) | DK0841923T3 (es) |
| ES (1) | ES2184876T3 (es) |
| NZ (1) | NZ311318A (es) |
| PT (1) | PT841923E (es) |
| WO (1) | WO1996040126A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| WO2000042023A1 (en) * | 1999-01-18 | 2000-07-20 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
| US6610721B2 (en) | 2000-03-17 | 2003-08-26 | Novo Nordisk A/S | Imidazo heterocyclic compounds |
| US6437147B1 (en) | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
| WO2002013821A1 (en) | 2000-08-17 | 2002-02-21 | Gliatech, Inc. | Novel alicyclic imidazoles as h3 agents |
| JPWO2005115993A1 (ja) * | 2004-05-31 | 2008-03-27 | 萬有製薬株式会社 | キナゾリン誘導体 |
| EP1707203A1 (en) | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| EP1717233A1 (en) | 2005-04-29 | 2006-11-02 | Bioprojet | Histamine H3-receptor ligands and their therapeutic application |
| EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| EP2740474A1 (en) | 2012-12-05 | 2014-06-11 | Instituto Europeo di Oncologia S.r.l. | Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2586562B1 (fr) * | 1985-09-02 | 1989-03-10 | Inst Nat Sante Rech Med | Composition pharmaceutique contenant de l'a-methylhistamine |
| DK0618905T3 (da) * | 1991-12-18 | 1995-12-04 | Schering Corp | Imidazolyl-alkyl-piperazin- og -diazepinderivater som histamin H3-agonister/antagonister |
-
1996
- 1996-06-06 ES ES96921378T patent/ES2184876T3/es not_active Expired - Lifetime
- 1996-06-06 DK DK96921378T patent/DK0841923T3/da active
- 1996-06-06 AT AT96921378T patent/ATE224193T1/de not_active IP Right Cessation
- 1996-06-06 PT PT96921378T patent/PT841923E/pt unknown
- 1996-06-06 JP JP9501805A patent/JPH11507631A/ja not_active Ceased
- 1996-06-06 DE DE69623784T patent/DE69623784T2/de not_active Expired - Fee Related
- 1996-06-06 EP EP96921378A patent/EP0841923B1/en not_active Expired - Lifetime
- 1996-06-06 CA CA002222652A patent/CA2222652A1/en not_active Abandoned
- 1996-06-06 AU AU62482/96A patent/AU713166B2/en not_active Ceased
- 1996-06-06 NZ NZ311318A patent/NZ311318A/xx unknown
- 1996-06-06 WO PCT/US1996/009498 patent/WO1996040126A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DK0841923T3 (da) | 2003-01-27 |
| WO1996040126A1 (en) | 1996-12-19 |
| AU713166B2 (en) | 1999-11-25 |
| CA2222652A1 (en) | 1996-12-19 |
| EP0841923A1 (en) | 1998-05-20 |
| AU6248296A (en) | 1996-12-30 |
| EP0841923A4 (en) | 1999-04-28 |
| ATE224193T1 (de) | 2002-10-15 |
| NZ311318A (en) | 2000-08-25 |
| DE69623784T2 (de) | 2003-05-15 |
| PT841923E (pt) | 2003-01-31 |
| EP0841923B1 (en) | 2002-09-18 |
| JPH11507631A (ja) | 1999-07-06 |
| DE69623784D1 (de) | 2002-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2184876T3 (es) | Derivados de imidazol sustituidos en 1h-4(5). | |
| ATE135701T1 (de) | Imidazolderivate, starke und selektive angiotensin-ii-rezeptor-antagonisten | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
| PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
| PE20040583A1 (es) | Nuevos derivados de benzimidazol | |
| EA201000331A1 (ru) | 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны | |
| ES2170859T3 (es) | Derivados de imidazol 1h-4(5)-sustituidos. | |
| CO6150176A2 (es) | Derivados de bencimidazol utiles en el tratamiento de los trastornos relacionados con el receptor vaniloide trpv1 | |
| ATE206122T1 (de) | Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind | |
| MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
| DE602005027230D1 (de) | Cgrp-rezeptorantagonisten | |
| EA200501122A1 (ru) | Замещенные алкиламидопиперидины | |
| PL340711A1 (en) | Derivatives of 5-(2-imidazolinamino)-benzimidazole, their production and application of them as antagonists of alpha-adrenergic receptors of improved metabolic stability | |
| PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
| ATE316078T1 (de) | 1,3,5-triazine-2,4,6-trione, herstellung und anwendungen als antagonisten der gonadotropin- freisetzenden hormonrezeptoren | |
| UY25864A1 (es) | Derivados de acetamida antagonistas de receptor de nk1 | |
| PE20090967A1 (es) | Derivados de imidazolidina 2,4-diona como moduladores del receptor npy y2 | |
| PE20050475A1 (es) | Antagonistas de la hormona concentradora de melanina | |
| ATE234098T1 (de) | 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors | |
| RU2002121777A (ru) | Новые производные имидазола | |
| RU2005102586A (ru) | 2,5-замещенные производные пиримидина в качестве антагонистов ix рецептора ccr-3 | |
| PE80099A1 (es) | Compuesto de amonio cuaternario | |
| DE60224509D1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden |